The purpose of this study was to investigate the immune-histochemical characteristics of upgraded malignancy from high-risk and borderline breast lesions, and to correlate the upgrade rates with clinical findings.
INTRODUCTION
Breast cancer is not a single disease entity, but a heteroge- ular hyperplasia, lobular carcinoma in situ) radial scar, papillary neoplasm, flat epithelial atypia (FEA), and mucocele-like lesions are included in high-risk breast lesions (5, 6) .
While the majority of high-risk and borderline lesions may require surgical excision given retrospective data for upgrade rates, close observation may be appropriate in certain selected cases (1, 2, 4, (6) (7) (8) (9) . Furthermore, prospective data are needed to better direct patient care and research focused on immunohistochemical characteristics is needed to advance medicine in breast care.
Therefore, in our study, we investigated the immunohistochemical characteristics of upgraded malignancy from high-risk or borderline breast lesions with the goal of comparing the clinical findings, tumor sizes, and pathologic types between high-risk and borderline lesions without and with cancer upgrade.
MATERIALS AND METHODS
This study was approved by our Institutional Review Board (Seoul St. Mary's Hospital, The Catholic University of Korea, KC16RISI0439). Informed consent was waived for this retrospective study.
Patients and Clinical Findings
From January 2011 to July 2015, we reviewed 9600 imageguided biopsies performed at our institution, including US-guided core needle biopsy and mammography-guided stereotactic vacuum-assisted biopsy. US-guided core needle biopsy was performed using a 14-gauge dual-action semiautomatic core biopsy needle with a 22-mm throw (Stericut with coaxial; TSK Laboratory, Tochigi, Japan). For prone-type mammography-guided stereotactic vacuum-assisted biopsies, the Mammo Test (Siemens AG, Munich, Germany) and Mammotome ® (Ethicon Endo-Surgery, Johnson & Johnson, Cincinnati, OH, USA) with an 11-gauge needle were used. We extracted all women with pathologic results of high-risk and borderline lesions, including ADH, lobular neoplasm, radial scar, papillary neoplasm, FEA, and mucocele-like lesions. Of these, 2 cases were excluded from the study due to follow-up loss during surveillance.
Ultimately, a total of 340 (3.5%, 340/9600) high-risk and borderline lesions were identified by the pathologist in biopsy samples and were followed on surveillance for more than 24 months.
Of them, 293 patients underwent surgical excision, and 47 patients were followed only by images. From the electronic medical records, age, breast cancer history, the method of detection (mammography or breast US), and biopsy method were analyzed. Lesion size was analyzed by measuring the longest diameter on mammography or breast US. 
RESULTS
The histopathologic results of the total of 340 lesions were as follows: 37.6% (128/340) were ADH, 3.2% (11/340) were lobular neoplasms, 12.6% (43/340) were radical scars, 27.1% (92/340) were papillary neoplasms, 6.5% (22/340) were FEAs, and 12.9% (44/340) were mucocele-like lesions. All forty-seven lesions (13.8%, 47/340) that were followed were stable during radiologic follow-up for more than 24 months, including 6 ADHs, 1 jksronline.org Table 1 demonstrated that cancer upgrade was significantly more likely occur with older age, larger tumor size, and pathologic types. In contrast, there were no differences in breast cancer history, detection image modality (mammography vs. US), and biopsy method.
Mean age was significantly different between patients without and with cancer upgrade [46.76 ± 10.82 years old and 50.14 
DISCUSSION
There are several studies assessing the correlations between (11) (12) (13) . In this study, we focused on investigating the immuohistochemical characteristics of upgraded malignancy from highrisk and borderline lesions and to correlate the upgrade rates with clinical findings.
According to the results of this study, cancer upgrade was significantly more likely occur with older age, larger tumor size, and pathologic types. The biopsy type (US-guided or stereotactic vacuum-associated biopsy) and lesion detection method did not affect the malignancy upgrade rate. These results are consistent with other studies (1, 14) .
Rethinking the standard for DCIS treatment is the current research trend (15) . There are many papers that distinguish prognosis or analysis of DCIS, an early cancer without invasion, from invasive ductal carcinoma (IDC) (3, 15, 16) . In this study, we also analyzed the cases that were upgraded to DCIS and IDC. In the study of Menes et al. (3) , most of the women with ADH on needle biopsy who were upgraded to cancer were found to have DCIS (82%, 101/123). More than half (56%, 10/18) of the women with lobular neoplasms who were upgraded to cancer 0 (0) 0 (0) 0 (0) 1 (4.8) 0 (0) 0 (0) 1 (1.6) Triple-(basal like) 1 (3.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.6) *Two missing data for ER, PR, HER2, Ki-67, EGFR, and subtype in the ADH group. ADH = atypical ductal hyperplasia, DCIS = ductal carcinoma in situ, EGFR = epidermal growth factor receptor, ER = estrogen receptor, HER2 = human epidermal growth factor receptor type 2, PR = progesterone receptor jksronline.org (6, 19, 20) .
With the development of biochemical science, precision medicine has emerged over the past decade and has changed the nature of therapies in patients with several types of cancers. Breast cancers are also newly classified into several subtypes according to combinations of molecular and cellular analyses, and categorized therapies, such as molecular target therapy, are expected to apply to the biomedical profile of a particular patient's disease (17, 21, 22) .
This study had several limitations. First, this is a retrospective study; therefore, it may be affected by selection bias. Second, the population is relatively small and included mixed indications for biopsy, heterogeneous pathologic types and surgery.
In conclusion, the cancer upgrade rates from high-risk and borderline breast lesions were higher in patients with older age, larger lesion sizes, and ADH. Most upgraded malignancies showed the Luminal A immunohistochemical type with good prognosis; lymph node metastasis was rare. 
